[ English | Bahasa Malaysia ] Today is 28th Jun 2022, 07:27 AM (Last updated: 27th Jun 2022)

Text Red Text Black Text Blue Text Green Text Smaller Text Reset Text Larger

Publication Details
Year :

2012

Journal :

Low SY, Tan BS, Choo HL, Tiong KH, Khoo AS and Leong CO (2012). Suppression of BCL-2 synergizes cisplatin sensitivity in nasopharyngeal carcinoma cells. Cancer Letter 314(2): 166-175

Abstract :

The efficacy of cisplatin for treating nasopharyngeal carcinoma (NPC) is limited by the dose-related toxicities and the development of resistance to cisplatin. Recent studies have shown that B cell lymphoma-2 (BCL-2) is overexpressed and confers chemoresistance in NPC. Thus, targeted therapy against BCL-2 may enhance the antitumour effects of chemotherapy by sensitizing the tumor cells to undergo apoptosis. This study eval uated the combined effects of BCL-2 inhibition and cisplatin in NPC cells. Our results demonstrate that inhibition of BCL-2 by small-hairpin RNA (shRNA) or the BCL-2 inhibitor YC137, synergizes cisplatin sensitivity in NPC cells that overexpress BCL-2. We also show that YC137 enhance cisplatin-ind uced apoptosis in HK1 and CNE1 cells through suppression of BCL-2 protein expression, induction of mitochondrial depolarization and activation of caspase 9 and caspase 3/7. These findings suggest that the combination of BCL-2 inhibition and cisplatin represents a promising strategy for treating NPC.

myGOV MAMPU JPA IKU MSC NMMR CRC MyHEALTH MOH Globinmed SPA krste.my

Notice

 

This site is best viewed on Firefox (24.0) with resolution higher than 1280 x 768 pixels.

Our Location

world

Located at Jalan Pahang, 50588 Kuala Lumpur, Malaysia. We operate from 8.00am - 5.00pm Monday - Friday. Click on the map image to launch Google Maps service.

Get in touch with us